Toba Hiroe, Nakagawa Yoshitsugu, Miki Shunsuke, Shimizu Takahiro, Yoshimura Akiko, Inoue Riyako, Asayama Jun, Kobara Miyuki, Nakata Tetsuo
Department of Clinical Pharmacology, Kyoto Pharmaceutical University, Kyoto, Japan.
Hypertens Res. 2005 Aug;28(8):689-700. doi: 10.1291/hypres.28.689.
Long-acting dihydropyridine calcium channel blockades have been shown to limit the progression of atherosclerosis and decrease the incidence of cardiovascular events in humans and animals. To investigate the vasoprotective effects beyond the blood pressure-lowering effects of these agents, amlodipine (20 mg/kg/ day) and manidipine (10 mg/kg/day) were administered by gavage to N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats for 2 weeks. L-NAME treatment (0.7 mg/ml in drinking water) significantly decreased the gene and protein expression of endothelial nitric oxide synthase (eNOS) and increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1) mRNA levels in the aorta, as determined by Western blotting and reverse transcription (RT)-polymerase chain reaction (PCR). Amlodipine and manidipine normalized the decreased expression of eNOS gene and protein, and attenuated the overexpression of NADPH oxidase, VCAM-1, and MCP-1 mRNA. Furthermore, amlodipine and manidipine prevented the L-NAME-induced increase in the angiotensin converting enzyme (ACE) mRNA content, thereby restoring control levels in the aorta. On the other hand, hydralazine treatment had no such effect in L-NAME treated rats. Furthermore, the increased expression of manganese superoxide dismutase (Mn-SOD) by L-NAME treatment was not affected by amlodipine, manidipine, or hydralazine. We concluded that the direct anti-inflammatory and antioxidative effects of calcium channel blockades in the aorta of rats with L-NAME-induced hypertension were not likely to have been mediated by the blood pressure-lowering action of these agents, but instead these beneficial effects appear to have been mediated by an augmentation of eNOS expression and by the inhibition of the expression of ACE.
长效二氢吡啶类钙通道阻滞剂已被证明可限制动脉粥样硬化的进展,并降低人类和动物心血管事件的发生率。为了研究这些药物除降压作用之外的血管保护作用,将氨氯地平(20毫克/千克/天)和马尼地平(10毫克/千克/天)经口灌胃给予N(G)-硝基-L-精氨酸甲酯(L-NAME)诱导的高血压大鼠,持续2周。L-NAME处理(饮用水中浓度为0.7毫克/毫升)显著降低了内皮型一氧化氮合酶(eNOS)的基因和蛋白表达,并增加了主动脉中烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶、血管细胞黏附分子-1(VCAM-1)和单核细胞趋化蛋白-1(MCP-1)的mRNA水平,这是通过蛋白质免疫印迹法和逆转录(RT)-聚合酶链反应(PCR)测定的。氨氯地平和马尼地平使eNOS基因和蛋白的降低表达恢复正常,并减弱了NADPH氧化酶、VCAM-1和MCP-1 mRNA的过表达。此外,氨氯地平和马尼地平阻止了L-NAME诱导的血管紧张素转换酶(ACE)mRNA含量增加,从而使主动脉中的水平恢复到对照水平。另一方面,肼屈嗪处理对L-NAME处理的大鼠没有这种作用。此外,L-NAME处理导致的锰超氧化物歧化酶(Mn-SOD)表达增加不受氨氯地平、马尼地平或肼屈嗪的影响。我们得出结论,钙通道阻滞剂在L-NAME诱导的高血压大鼠主动脉中的直接抗炎和抗氧化作用不太可能是由这些药物的降压作用介导的,相反,这些有益作用似乎是由eNOS表达的增强和ACE表达的抑制介导的。